TY - JOUR
T1 - Neurostimulation for cognitive enhancement in Alzheimer's disease (the NICE-AD study)
T2 - A randomized clinical trial
AU - Gulley, Emma
AU - Verghese, Joe
AU - Blumen, Helena M.
AU - Ayers, Emmeline
AU - Wang, Cuiling
AU - Portenoy, Russell K.
AU - Zwerling, Jessica L.
AU - Weiss, Erica
AU - Knotkova, Helena
N1 - Funding Information:
This work is supported by a grant from the National Institutes of Health (1 R01 AG068167-01). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Publisher Copyright:
© 2021 Future Medicine Ltd.. All rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - New therapies for symptoms in Alzheimer's disease (AD) are urgently needed. Prior studies suggest that transcranial direct current stimulation (tDCS), a noninvasive neuromodulatory method, may be a safe and potentially effective treatment, but conclusions have been limited by small-sample sizes and brief stimulation protocols. This double-blind randomized trial involving 100 older adults with mild-to-moderate AD examines effects of 6 months of at-home active tDCS or sham delivered over the dorsolateral prefrontal cortex. The primary outcome is global cognitive performance. Secondary outcomes include executive-control/spatial selective attention, functional neuroplasticity, depressive symptoms, quality of life and the durability of effects 3 months after the stimulation period. The results will provide evidence on the efficacy of multimonth at-home tDCS in the AD treatment. =Clinical trial identifier NCT 04404153 (Clinicaltrials.gov).
AB - New therapies for symptoms in Alzheimer's disease (AD) are urgently needed. Prior studies suggest that transcranial direct current stimulation (tDCS), a noninvasive neuromodulatory method, may be a safe and potentially effective treatment, but conclusions have been limited by small-sample sizes and brief stimulation protocols. This double-blind randomized trial involving 100 older adults with mild-to-moderate AD examines effects of 6 months of at-home active tDCS or sham delivered over the dorsolateral prefrontal cortex. The primary outcome is global cognitive performance. Secondary outcomes include executive-control/spatial selective attention, functional neuroplasticity, depressive symptoms, quality of life and the durability of effects 3 months after the stimulation period. The results will provide evidence on the efficacy of multimonth at-home tDCS in the AD treatment. =Clinical trial identifier NCT 04404153 (Clinicaltrials.gov).
KW - Alzheimer's disease
KW - at-home tDCS
KW - clinical trial protocol
KW - dementia
KW - noninvasive neurostimulation
KW - transcranial direct current stimulation (tDCS)
UR - http://www.scopus.com/inward/record.url?scp=85115114702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115114702&partnerID=8YFLogxK
U2 - 10.2217/nmt-2020-0061
DO - 10.2217/nmt-2020-0061
M3 - Article
C2 - 34240627
AN - SCOPUS:85115114702
SN - 1758-2024
VL - 11
SP - 277
EP - 288
JO - Neurodegenerative disease management
JF - Neurodegenerative disease management
IS - 4
ER -